stockrow
Saturday 7 November 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −43.4%
- Total debt
- −15.7%
Quarter to June 2026, against a year earlier
25.16
3.29
+15.04%
Follow ANRO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | — | — | — | 3 | 3 | 3 | 0.0% | |
| Gross margin, % | — | — | — | — | — | 100.00 | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | (9) | (28) | (36) | (61) | (63) | (84) | +62.0% | ||||||
| EBT margin, % | — | — | — | — | — | (4,374.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +4,374.8 pt | ||||||
| Net income | — | — | — | — | — | (9) | (28) | (36) | (61) | (63) | (84) | +62.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (3.81) | (8.04) | (9.73) | (2.50) | (2.19) | (2.42) | (12.9%) | ||||||
| Cash flow | — | — | — | — | — | (3.84) | (5.92) | (8.96) | (1.93) | (1.79) | (1.59) | (17.3%) | ||||||
| Capex | — | — | — | — | — | (0.28) | (0.21) | (0.13) | (0.08) | 0.00 | (0.01) | (76.9%) | ||||||
| Free cash flow | — | — | — | — | — | (4.12) | (6.13) | (9.09) | (2.01) | (1.80) | (1.61) | (18.8%) | ||||||
| Book value | — | — | — | — | — | 10.64 | 9.82 | 18.71 | 6.16 | 5.24 | 5.12 | (16.2%) | ||||||
| Shares, m | — | — | — | — | — | 2 | 3 | 4 | 25 | 29 | 33 | +86.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | 0.00 | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | 0.00 | — | — | — | — | 4.91 | — | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | (0.13) | — | — | — | — | (12.38) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (9) | (20) | (33) | (47) | (52) | (68) | +53.8% | |||||
| Capex | — | — | — | — | — | (1) | (1) | 0 | (2) | 0 | (1) | (56.7%) | ||||||
| Free cash flow | — | — | — | — | — | (10) | (21) | (34) | (49) | (52) | (69) | +51.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 26 | 44 | 80 | 159 | 166 | 231 | +59.2% | |||||
| Net debt | — | — | — | — | — | (26) | (39) | (73) | (157) | (157) | (225) | +57.3% | ||||||
| Shareholders’ equity | — | — | — | — | — | 26 | 34 | 70 | 151 | 151 | 219 | +55.7% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (69.58) | (52.81) | (46.51) | (34.92) | (40.90) | (34.9) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 108.91 | 65.96 | (153.99) | (41.80) | (49.17) | (41.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 63 | 63 | 76 | 68 | — | +2.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2021
Alto Neuroscience, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $874.5M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $870.6M | 34.2× | — (loss-making) | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $867.9M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LTGO Latigo Biotherapeutics Inc | $862.6M | — | — | — | n/m | — | — | 0.00% | Compare |
| ANRO Alto Neuroscience, Inc. | $858.2M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | |
| RIGL Rigel Pharmaceuticals, Inc. | $853.9M | 2.4× | 16.4× | +16.45% (above 0%: growing) | −54.84% (below 0%: shrinking) | +43.90% (above 0%: growing) | 86.67% | 21.15% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $843.6M | — (loss-making) | — (loss-making) | +81.59% (above 0%: growing) | n/m | +61.43% (above 0%: growing) | 83.20% | (50.30%) | Compare |
| Median of peers | $869.3M | — | — | +20.86% | — | −1.50% | 84.94% | 0.00% |
Pay and ownership Proxy statement filed 26 March 2026
Ownership
Directors and executive officers, together
11.25%
Alpha Wave Ventures II, LP
11.61%
Entities affiliated with Commodore Capital LP
9.99%
Entities affiliated with Perceptive Advisors LLC
9.99%
Entities affiliated with Point72 Asset Management
8.69%
Vestal Point Capital LP
7.78%
Amit Etkin, M.D., Ph.D.
5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement